Core Insights - Labcorp (LH) has expanded its precision oncology portfolio with new test offerings for solid tumors and hematologic malignancies, along with enhanced biopharma solutions aimed at accelerating clinical trials and companion diagnostic development [1][8]. Company Developments - Following the announcement, Labcorp shares increased by 0.9%, closing at $248.97, with a focus on oncology expected to drive growth opportunities, projected to grow up to 3x faster than other therapeutic areas [2]. - Labcorp's market capitalization stands at $20.84 billion, with earnings expected to grow by 10.2% and revenues by 6.9% in 2025, based on the Zacks Consensus Estimate [3]. - The company introduced new NGS panels for myeloid, lymphoid, and pan-heme indications, enhancing genomic coverage and actionable insights for hematologic malignancies [4]. - The launch of the Rapid AML Panel aims to improve testing for acute myeloid leukemia, while the OmniSeq INSIGHT test will now include homologous recombination deficiency (HRD) testing for ovarian cancer patients [5]. - Labcorp has launched Labcorp Plasma Focus, a solid tumor liquid biopsy test, and an enhanced digital pathology platform to support companion diagnostic development [6][9]. Industry Prospects - The global precision oncology market is projected to exceed $312.33 billion by 2034, growing at a compound annual growth rate of 10% from 2024 to 2034, driven by rising cancer prevalence and advancements in technologies like next-generation sequencing [10]. - Labcorp's recent acquisition of select assets from Incyte Diagnostics' clinical testing business includes several same-day testing labs and key anatomic pathology facilities [11]. Stock Performance - Over the past year, Labcorp shares have increased by 27.7%, significantly outperforming the industry, which saw a decline of 2.3% [12].

Core Insights - InStride has facilitated a partnership between Arizona State University (ASU) and Labcorp to launch a Master of Science in Cytology, addressing a critical shortage of cytotechnologists in the U.S. [1][2] - The program aims to provide accessible, high-quality training to meet the growing demand for cytotechnologists, with the first cohort starting in January 2025 [1][5]. Group 1: Partnership and Program Development - The collaboration was initiated at InStride's annual IMPACT summit, where leaders from ASU and Labcorp recognized the urgent need for trained cytotechnologists [3]. - The program was developed in just six months, showcasing the ability of universities to respond quickly to industry workforce needs [2][4]. Group 2: Educational Approach and Accessibility - The program combines ASU's online education expertise with hands-on clinical training, making cytology education available nationwide, unlike traditional programs concentrated in specific regions [5]. - Future expansions will allow enrollment beyond Labcorp employees and introduce undergraduate and certificate pathways in laboratory medicine [5]. Group 3: Industry Impact and Workforce Solutions - This partnership provides Labcorp with a scalable education solution to address workforce needs while offering clinical lab professionals a flexible pathway to advance their careers [6]. - Cytology is crucial for cancer screening and diagnosis, and the collaboration enables Labcorp employees to stay updated with advancements in diagnostic testing [7].

Core Insights - Labcorp has expanded its precision oncology portfolio with new test offerings for solid tumors and hematologic malignancies, along with enhanced biopharma solutions to accelerate clinical trials and companion diagnostic development [1][2] Diagnostics: New Solutions for Solid Tumor and Hematologic Malignancies - The company aims to improve patient access to testing and identify eligibility for targeted therapies through new diagnostic solutions [2] - New NGS panels for myeloid, lymphoid, and pan-heme indications provide broader genomic coverage and actionable insights for hematologic malignancies [4] - The launch of a Rapid AML Panel enhances testing for acute myeloid leukemia, enabling timely treatment decisions [4] - Expansion of OmniSeq® INSIGHT includes homologous recombination deficiency (HRD) testing to identify ovarian cancer patients likely to benefit from targeted therapies [4] - New FDA-approved companion diagnostics include HER2 categorization for breast cancer and the VENTANA® MET (SP44) RxDx Assay for non-squamous non-small cell lung cancer [4] Biopharma Laboratory Services: Accelerating Clinical Trials and Companion Diagnostic Development - Labcorp is enhancing global trial consistency and collaboration with biopharma customers [3] - The global expansion of Labcorp® Plasma Focus, a solid tumor liquid biopsy test, is now available in Geneva and Shanghai, complementing Labcorp Tissue® Complete for pan-solid tumors [4] - An enhanced digital pathology platform has been launched across global central labs, utilizing advanced scanning and image management systems for improved diagnostic insights [4] Company Overview - Labcorp is a global leader in laboratory services, supporting over 75% of new drugs approved by the FDA in 2024 and performing over 700 million tests annually [5]

Core Viewpoint - Labcorp's shares have increased by approximately 2.5% since the last earnings report, which is underperforming compared to the S&P 500 [1] Group 1: Earnings and Estimates - Recent estimates for Labcorp have trended downward over the past month [2] - The magnitude of estimate revisions for Labcorp has been net zero, indicating stability in expectations [4] Group 2: VGM Scores and Rankings - Labcorp has a subpar Growth Score of D and a similar score for momentum, but a B grade for value, placing it in the top 40% for this investment strategy [3] - The overall VGM Score for Labcorp is C, which is relevant for investors not focused on a single strategy [3] - Labcorp holds a Zacks Rank of 3 (Hold), suggesting an expectation of an in-line return in the coming months [4] Group 3: Industry Performance - Labcorp is part of the Zacks Medical - Dental Supplies industry, where West Pharmaceutical Services has seen a slight gain of 0.1% over the past month [5] - West Pharmaceutical reported revenues of $698 million for the last quarter, reflecting a year-over-year increase of 0.4% [5] - The expected earnings for West Pharmaceutical for the current quarter is $1.51 per share, indicating a year-over-year decline of 0.7% [6]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...

Financial Data and Key Metrics Changes - LabCorp reported exceptional results in 2024, with strong momentum heading into 2025, indicating a positive outlook for financial performance [4] - At least 91% of shares voted in favor of the nonbinding advisory approval of the company's compensation for named executive officers, reflecting shareholder confidence [30] - The approval rate for the company's 2025 omnibus incentive plan was at least 94%, and for the employee stock purchase plan, it was at least 99% [30] Business Line Data and Key Metrics Changes - The diagnostics and biopharma laboratory services businesses made meaningful advances through organic growth and transformative acquisitions, contributing to the overall success of LabCorp [4] Market Data and Key Metrics Changes - No specific market data or key metrics changes were provided in the meeting [0] Company Strategy and Development Direction - LabCorp is focused on improving health and lives while generating attractive returns for shareholders, positioning itself well for future growth [4] - The company emphasizes ethical and regulatory responsibilities in its biopharma laboratory services, particularly regarding animal welfare and research integrity [35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in LabCorp's positioning for continued success in 2025, highlighting the importance of their strategic initiatives [4] - The company is committed to high standards of animal care and welfare, which is fundamental to sound scientific research [35] Other Important Information - The meeting included the election of directors, approval of executive compensation, and ratification of the independent registered public accounting firm for 2025, all of which passed with significant support from shareholders [30] Q&A Session Summary Question: What specific measures is LabCorp taking to mitigate biosafety and public health risks associated with research animals? - LabCorp takes its ethical and regulatory responsibilities seriously, ensuring the health and wellness of research animals, which is fundamental to scientific research [35] - The company has a dedicated global team to establish high standards of animal care and welfare, proactively identifying and mitigating risks [36]

BURLINGTON, N.C., May 8, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that its Annual Meeting of Shareholders will be webcast live on May 15 at 9:00 a.m. ET and can be viewed online on the Labcorp Investor Relations website. An archived replay of the webcast will be available for one year.About LabcorpLabcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmac ...

Labcorp Holdings (LH) Q1 2025 Earnings Call April 29, 2025 02:09 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the Q1 twenty twenty five LabCorp Holdings Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your ques ...

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control, including without limitation: (i) the effect of the holding company reorganization on the company's business generally; (ii) the failure to receive tax-free treatment with respect to the spin-off of the company's Clinical Development and Commercialization Services business, now Fortrea Holdings Inc. for U.S. federal income purposes; (iii) the impact of spin-off rela ...

or UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 For the transition period from ______ to ______ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Commission file number 1-11353 LABCORP HOLDINGS INC. Indicate by check mark whether the registrant has submitted electronically every Interactive Data F ...